The structure and function of CD26 in the T-cell immune response

Immunological Reviews

Volumn 161, Issue , 1998, Pages 55-70

  Morimoto, Chikao ^a   Schlossman, Stuart F ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; CD4 ANTIGEN; CD45 ANTIGEN; DIPEPTIDYL PEPTIDASE IV;

APOPTOSIS; HELPER CELL; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE DIFFERENTIATION; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

ADENOSINE DEAMINASE; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD26; ANTIGENS, CD45; APOPTOSIS; CELL DIVISION; HIV INFECTIONS; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN-TYROSINE-PHOSPHATASE; T-LYMPHOCYTES;

EID: 0031908130     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1998.tb01571.x     Document Type: Review

References (85)

1. Geppert TD, Davis LS, Gur H, Wacholtz MC, Lipsky PE. Accessory cell Signals involved in T cell activation. Immunol Rev 1990;117:5-66.
2. Dang NH, Torimoto Y, Deusch K, Schlossman SF, Morimoto C. Co-mitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol 1990;144:4092-4100.
3. Morimoto C, et al. 1F7, a novel cell surface molecule involved in helper function of CD4 cells. J Immunol 1989;143:3430-3439.
4. Fox DA, et al. Tal, a novel 105KD human T cell activation antigen defined by a monoclonal antibody. J Immunol 1984;133:1250-1256.
5. Fleischer B. A novel pathway of human T cell activation via a 103KD T cell activation antigen. J Immunol 1987;138:1346-1350.
6. Dang NH, Hafler DA, Schlossman SF, Breitmeyer JB. FcR-mediated crosslinking of Ta1 (CDw26) induces T cell activation. Cell Immunol 1990;125:42-57.
7. Fleischer B, Sturm E, Devries JE, Spits H. Triggering of cytotoxic T lymphocytes and NK cells via the Tp103 pathway is dependent on the expression of the T cell receptor/CD3 complex. J Immunol 1988;141:1103-1107.
8. Dang NH, et al. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody: Analysis of surface expression and human T cell activation. J Immunol 1990;145:3963-3971.
9. Dang NH, Torimoto Y, Schlossman SF, Morimoto C. Human CD4 helper T cell activation: Functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family. J Exp Med 1990;172:64.9-652.
10. Ulmer AJ, Mattern T, Feller AC, Heymann E, Flad HD. CD26 antigen is a surface dipeptidyl peptidase IV (DPPIV) as characterized by monoclonal antibodies clone TII-19-4-7 and 4ELIC7. Scand J Immunol 1990;31:429-435.
11. Hegen M, Niedobitek G, Klein CB, Stein H, Fleischer B. The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J Immunol 1990;144:2908-2914.
12. Torimoto Y, Dang NH, Tanaka T, Prado C, Schlossman SF, Morimoto C. Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various monoclonal antibodies. Mol Immunol 1992;29:183-192.
13. Kenny AJ, et al. Dipeptidyl peptidase IV, a kidney brush-border serine peptidase. Biochem J 1976;155:169-182.
14. Tanaka T, et al. Cloning and functional expression of the T cell activation antigen CD26. J Immunol 1992;149:481-486.
15. Brenner S. The molecular evolution of genes and proteins: a tale of two series. Nature 1988;334:528-530.
16. Hong W, Doyle D. cDNA cloning for a bile canaliculus domain-specific membrane glycoprotein of rat hepatocytes. Proc Natl Acad Sci USA 1987;84:7962-7965.
17. Ogata S, Misumi Y, Ikehara Y. Primary structure of rat liver dipeptidyl peptidase IV deduced from its cDNA and identification of the NH2-terminal signal sequence as the membrane-anchoring domain. J Biol Chem 1989;264:3596-3601.
18. Marguet D, Bernard A, Vivier I, Darmoul D, Naquet P, Pierres M. cDNA cloning for mouse thymocyte-activating molecule. J Biol Chem 1992;267:2200-2208.
19. Dang NH, Torimoto Y, Tanaka T, Daley JF, Schlossman SF, Morimoto C. 1F7 (CD26): a marker of lhymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation. J Immunol 1991;147:2825-2832.
20. Gorrel MD, Wickson J, Mc Caughan GW. Expression of the rat CD26 antigen (DPPIV) on subpopulations of rat lymphocytes. Cell Immunol 1991;134:205-210.
21. Flentke GR, Munoz E, Huber BT, Plaut AG, Kettner CA, Bachovchin WW. Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boro-Pro dipeptides and use of these inhibitors to examine the role of DP-IV in T cell function. Proc Natl Acad Sci USA 1991;88:1556-1559.
22. Schon E, et al. The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol 1987;17:1821-1826.
23. Tanaka T, Kameoka J, Yaron A, Schlossman SF, Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzyme activity. Proc Natl Acad Sci USA 1993;90:4386-4390.
24. Tanaka T, et al. Enhancement of antigen-induced T cell proliferation by soluble CD26/DPPIV. Proc Natl Acad Sci USA 1994;91:3082-3086.
25. Davis NG, Model P. An artificial anchor domain: hydrophobicity suffices to stop transfer. Cell 1985;41:607-614.
26. Schnittman SM, Lane HC, Greenhouse I, Justement JS, Baseler M, Fauci AS. Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: Evidence for a role in the selective T cell functional defects observed in infected individuals. Proc Natl Acad Sci USA 1990;87:6058-6062.
27. Blazquez MV, et al. Selective decrease of CD26 expression in T cells from HIV-infected individuals. J Immunol 1992;149:3073-3077.
28. Viscidi RP, Mayur K, Ledermen HM, Frankel AD. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 1989;246:1606-1608.
29. Subramanyam M, Gutheil WG, Bachovchin WW, Huber BT. Mechanism of HIV-1 tat induced inhibition of antigen-specific T cell responsiveness. J Immunol 1993;150:2544-2553.
30. Gutheil WG, et al. Human immunodeficiency virus 1 tat binds to dipeptidyl peptidise IV (CD26): A possible mechanism for Tat's immunosuppressive activity. Proc Natl Acad Sci USA 1994;91:6594-6598.
31. Callabaut C, Krust B, Jacotot E, Hovanessian AG. T cell activation antigen, CD26, as a cofactor for entry of HIV in CD4+ cells. Science 1993;262:2045-2050.
32. Morimoto C, Lord CI, Zhang C, Duke-Cohan JS, Letvin NL, Schlossman SF. Role of CD26/dipeptidyl peptidase IV in human immunodeficiency virus type 1 infection and apoptosis. Proc Natl Acad Sci USA 1994;91:9960-9964.
33. Broder CC, Nussbaum O, Gutheil WG, Bachovchin WW, Berger EA. CD26 antigen and HIV fusion? Science 1994;264:1156-1159.
34. Patience C, McKnight A, Clapham PR, Boyd MT, Weiss RA, Schultz TF. CD26 antigen and HIV fusion? Science 1994;264:1159-1160.
35. Camerini D, Planelles V, Chen IY. CD26 antigen and HIV fusion? Science 1994;264:1160-1161.
36. Ameisen JC, Capron A. Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis [review]. Immunol Today 1991;12:102-105.
37. Gougen ML, Montagnier L. Apoptosis in AIDS. Science 1993;260:1269-1270.
38. Itoh N, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-243.
39. Trauth BC, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-305.
40. Smith CA, Farrah T, Goodwin RG. The receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994;76:959-962.
41. Torimoto Y, Dang NH, Vivier E, Tanaka T, Schlossman SF, Morimoto C. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol 1991;147:2514-2517.
42. Vivier E, et al. Expression and tyrosine phosphorylation of the T cell receptor ζ-subset in human thymocytes. J Immunol 1991;146:1142-1148.
43. Ashwell JD, Klauser R. Genetic and mutational analysis of the T cell antigen receptor. Annu Rev Immunol 1990;8:139-167.
44. Hegen M, Kameoka J, Dong R-P, Schlossman SF, Morimoto C. Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase. Immunology 1997;90:257-264.
45. Taga T, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989;58:573-581.
46. Robb RJ, Greene WC. Internalization of interleukin-2 is mediated by the β chain of the high-affinity interleukin-2 receptor. J Exp Med 1987;165:1201-1206.
47. Volarevic S, Burns CM, Sussman JJ, Ashwell JD. Intimate association of Thy-1 and the T cell antigen receptor with the CD45 tyrosine phosphatase. Proc Natl Acad Sci USA 1990;87:7085-7089.
48. Schraven B, Samatag Y, Altevogt P, Meuer S. Association of CD2 and CD45 on human T lymphocytes. Nature 1990;345:71-74.
49. Rudd CE, Morimoto C, Wong L-L, Schlossman SF. The subdivision of the T4(CD4) subset is the basis of the differential expression of L-C/T200 antigens. J Exp Med 1987;166:1758-1773.
50. Terry LA, Brown MH, Beverly PCL. The monoclonal antibody, UCL-1, recognizes a 180,000 MW component of the human leukocyte-common antigen, CD45. Immunology 1988;64:331-336.
51. Charbonneau H, Tonka NK, Wlash A, Fischer EH. The leukocyte common antigen (CD45): a putative receptor-linked protein tyrosine phosphatase. Proc Natl Acad Sci USA 1988;85:7182-7186.
52. Ledbetter JA, Tonka NK, Fischer EH, Clark EA. CD45 regulates signal transduction and lymphocyte activation by specific association with receptor molecules on T or B cells. Proc Natl Acad Sci USA 1988;85:8628-8632.
53. Pingel JT, Thomas ML. Evidence that the leukocyte-common antigen is required for antigen-induced T lymphocyte proliferation. Cell 1989;58:1055-1065.
54. Koretzky GA, Picus J, Thomas ML, Weiss A. Tyrosine phosphatase is essential for coupling T cell antigen receptor to the phosphatidyl inositol pathway. Nature 1990;346:66-68.
55. Ostergaard HL, et al. Expression of CD45 alters phosphorylation of the lck tyrosine protein kinase in murine lymphoma T cell lines. Proc Natl Acad Sci USA 1989;86:8959-8963.
56. lck by the CD45 phosphoprotein phosphatase. Proc Natl Acad Sci USA 1989;86:6302-6306.
57. lck. Nature 1989;338:257-259.
58. lck. J Exp Med 1990;172:347-350.
59. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 1993;261:466-169.
60. Daddona PE, Shewach DS, Kelley WN, Argos P, Markham AF, Orkin SH. Human adenosine deaminase: cDNA and complete primary amino acid sequence. J Biol Chem 1984;259:12101-12106.
61. Schrader WP, Miczek AD, West CA, Samsonoff WA. Evidence for receptor-mediated uptake of adenosine deaminase in rabbit kidney. J Histochem Cytochem 1988;36: 1481-1487.
62. Aran JM, Colmer D, Matutes E, Vives-Corrons JL, Franco RJ. Presence of adenosine deaminase on the surface of mononudear blood cells: Immunochemical localization using light and electron microscopy. J Histochem Cytochem 1991;39: 1001-1008.
63. Hirshhorn R. Adenosine deaminase deficiency. In: Rosen FS, Seligman M, eds. Immunodeficiency Reviews. Vol 2. London: Academic Publications: 1990. p. 175-198.
64. Dong R-P, et al. Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function. Mol Immunol (In press).
65. Dong R-P, et al. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J Immunol (In press).
66. Dong R-P, et al. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 1996;156:1349-1355.
67. Buc HA, Moncion A, Hamet M, Houllier A-M, Thuilier L, Perignon J-L. Influence of adenosine deaminase inhibition on the phosphoinositide turnover in the initial stages of human T cell activation. Eur J Immunol 1990;20:611-615.
68. Olsson RA, Pearson JD. Cardiovascular purinoreceptors. Physiol Rev 1990;70:761-845.
69. Stiles GL. Adenosine receptors. J Biol Chem 1992;267:6451-6454.
70. Smith JW, Steiner AL, Parker CW. Human lymphocyte metabolism: effects of cyclic and noncyclic nucleotides on stimulation by phytohemagglutinin. J Clin Invest 1971;50:442-448.
71. Green H, Chan TS. Pyrimidine starvation induced by adenosine in fibroblasts and lymphoid cells: role of adenosine deaminase. Science 1973;182:836-837.
72. Carson DA, Seegmiller JE. Effect of adenosine deaminase inhibition upon human lymphocyte blastogenesis. J Clin Invest 1976;57:274-281.
73. Hovi T, Smyth JF, Allison AC, Williams SC. Role of adenosine deaminase in lymphocyte proliferation. Clin Exp Immunol 1976;23:395-403.
74. Ruers TJM, Buurman WA, van der Linden CJ. 2'deoxycoformycin and deoxyadenosine affect IL-2 production and IL-2 receptor expression of human T cells. J Immunol 1987;138:116-122.
75. Kizaki H, Shimada H, Ohsaka F, Sakurada T. Adenosine, deoxyadenosine, and deoxyguanosine induce DNA cleavage in mouse thymocytes. J Immunol 1988;141:1652-1657.
76. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985;75:377-383.
77. Szondy Z. Adenosine stimulates DNA fragmentation in human thymocytes by Ca+-mediated mechanisms. Biochem J 1994;304:877-885.
78. Morrison ME, Vijayasaradhi S, Engelstein D, Albino AP, Houghton AN. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med 1993;177:1135-1143.
79. Mackenzie WM, Hoskin DW, Blay J. Adenosine inhibits the adhesion of anti-CD3 activated killer lymphocytes to adenocarcinoma cells through an A3 receptor. Cancer Res 1994;54:3521-3526.
80. Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood 1994;84:4061-4063.
81. Matsuyama J, Berman JS, Cruikshank WW, Morimoto C, Center DM. Evidence for recent as well as long term activation of T cells migrating through endothelial cell monolayers in vitro. J Immunol 1992;148:1367-1374.
82. Hafler DA, Fox DA, Manning ME, Schlossmin SF, Reinherz EL, Weiner HL. In vitro activation of T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med 1985;312:1405-1410.
83. Nakao H, et al. Increment of Ta1-positive cells in peripheral blood from patients with rheumatoid arthritis. J Rheumatol 1989;16:904-910.
84. Eguchi K, et al. Increment in the Ta1+ cells in the peripheral blood and thyroid tissue of patients with Graves' disease. J Immunol 1989;142:4233-4240.
85. Cronstein BN, Naime D, Olstead E. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed site diminishes leukocyte accumulation - an in vivo model of inflammation. J Clin Invest 1993;92:2675-2682.